Akèy › Kansè fwa (Kasinòm epatoselilè) › Minnesota › Rochester
Etid klinik pou Kansè fwa (Kasinòm epatoselilè) nan Rochester, MN
12 etid pou Kansè fwa (Kasinòm epatoselilè) ap chèche patisipan nan sit nan ak bò kote Rochester (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Ap rekriteFaz 1/2
- Mayo Clinic in Rochester, Rochester
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Ap rekriteFaz 1
- Mayo Clinic Rochester, Rochester
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #68, Rochester
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Ap rekriteFaz 1/2
- Research Facility, Rochester
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Ap rekriteFaz 3
- Research Site, Rochester
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Mayo Clinic, Rochester
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Ap rekriteFaz 2
- Mayo Clinic in Rochester, Rochester
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
Ap rekriteEtid obsèvasyon
- Mayo Clinic, Rochester
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Ap rekriteFaz 1
- Clinical Trial Site, Rochester
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Ap rekriteEtid obsèvasyon
- Mayo Clinic in Rochester, Rochester
The Dragon PLC Trial (DRAGON-PLC)
Ap rekrite
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Ap rekriteFaz 1/2
- Mayo Clinic in Minnesota, Rochester
Etid Kansè fwa (Kasinòm epatoselilè) nan lòt vil
- Houston, TX31 etid
- New York City, NY24 etid
- Dallas, TX19 etid
- Los Angeles, CA19 etid
- Boston, MA18 etid
- Cleveland, OH18 etid
- Philadelphia, PA16 etid
- Chicago, IL16 etid
- Pittsburgh, PA15 etid
- San Francisco, CA14 etid
- Orange, CA14 etid
- Jacksonville, FL14 etid
Lòt etid nan Rochester
- Kansè nan tete42 etid
- Kansè Poumon ki pa ti selil37 etid
- Kansè Metastatik31 etid
- Kansè (tout kalite)30 etid
- Kansè ovè29 etid
- Kansè kolorektal29 etid
- Myelom Miltip24 etid
- Ensifizyans kadyak22 etid
- Kansè pwostat22 etid
- Kansè pankreyas22 etid
- Kansè Endomèt20 etid
- Kansè poumon20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.